Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Shanghai Henlius Biotech, Inc. has announced a special meeting for H shareholders on January 22, 2025, to vote on a merger agreement with Shanghai Fosun New Medicine Research Company Limited. The merger, intended to absorb Henlius into Fosun, requires approval by at least 75% of independent shareholders. Successful approval could significantly impact the company’s stock value and future business operations.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.